Literature DB >> 17379840

Vascular functions of the plasminogen activation system.

William P Fay1, Nadish Garg, Madhavi Sunkar.   

Abstract

The plasminogen activator (PA) system, which controls the formation and activity of plasmin, plays a key role in modulating hemostasis, thrombosis, and several other biological processes. While a great deal is known about the function of the PA system, it remains a focus of intensive investigation, and the list of biological pathways and human diseases that are modulated by normal and pathologic function of its components continues to lengthen. Because of remarkable advances in molecular genetics, the laboratory mouse has become the most useful animal system to study the normal and pathologic functions of the PA system. The purpose of this review is to summarize studies that have used genetically modified mice to examine the functions of the PA system in hemostasis and thrombosis, intimal hyperplasia after vascular injury, and atherosclerosis. Particular emphasis is placed on the vascular functions of PA inhibitor-1, a key regulator of the PA system, and the multiple variables that appear to account for the complex role of PA inhibitor-1 in regulating vascular remodeling. Lastly, the strengths and limitations of using mice to model human vascular disease processes are discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17379840     DOI: 10.1161/ATVBAHA.107.140046

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  42 in total

1.  Fibrinogen counteracts the antiadhesive effect of fibrin-bound plasminogen by preventing its activation by adherent U937 monocytic cells.

Authors:  V K Lishko; I S Yermolenko; H Owaynat; T P Ugarova
Journal:  J Thromb Haemost       Date:  2012-06       Impact factor: 5.824

2.  Distinct clinical and immunologic profiles in severe malarial anemia and cerebral malaria in Zambia.

Authors:  Philip E Thuma; Janneke van Dijk; Rick Bucala; Zufan Debebe; Sergei Nekhai; Thea Kuddo; Mehdi Nouraie; Günter Weiss; Victor R Gordeuk
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

3.  Reprogrammed streptokinases develop fibrin-targeting and dissolve blood clots with more potency than tissue plasminogen activator.

Authors:  I Y Sazonova; R A McNamee; A K Houng; S M King; L Hedstrom; G L Reed
Journal:  J Thromb Haemost       Date:  2009-06-30       Impact factor: 5.824

Review 4.  Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases.

Authors:  Anna Tjärnlund-Wolf; Helen Brogren; Eng H Lo; Xiaoying Wang
Journal:  Stroke       Date:  2012-08-09       Impact factor: 7.914

Review 5.  Molecular pathogenesis of genetic and sporadic aortic aneurysms and dissections.

Authors:  Ying H Shen; Scott A LeMaire
Journal:  Curr Probl Surg       Date:  2017-02-03       Impact factor: 1.909

Review 6.  Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.

Authors:  Matteo Cesari; Marco Pahor; Raffaele Antonelli Incalzi
Journal:  Cardiovasc Ther       Date:  2010-07-07       Impact factor: 3.023

7.  Plasminogen-stimulated airway smooth muscle cell proliferation is mediated by urokinase and annexin A2, involving plasmin-activated cell signalling.

Authors:  A G Stewart; Y C Xia; T Harris; S Royce; J A Hamilton; M Schuliga
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

8.  Plasminogen mediates the atherogenic effects of macrophage-expressed urokinase and accelerates atherosclerosis in apoE-knockout mice.

Authors:  Michal Kremen; Ranjini Krishnan; Isaac Emery; Jie Hong Hu; Katherine I Slezicki; Alyssa Wu; Kun Qian; Liang Du; Abigail Plawman; April Stempien-Otero; David A Dichek
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-28       Impact factor: 11.205

Review 9.  Vein graft failure: from pathophysiology to clinical outcomes.

Authors:  Margreet R de Vries; Karin H Simons; J Wouter Jukema; Jerry Braun; Paul H A Quax
Journal:  Nat Rev Cardiol       Date:  2016-05-19       Impact factor: 32.419

10.  Circulating levels of inflammatory markers in intrauterine growth restriction.

Authors:  Theodora Boutsikou; George Mastorakos; Marialena Kyriakakou; Alexandra Margeli; Demetrios Hassiakos; Ioannis Papassotiriou; Christina Kanaka-Gantenbein; Ariadne Malamitsi-Puchner
Journal:  Mediators Inflamm       Date:  2010-06-03       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.